the demonstration that some of the resistant cell lines have a decreased accumulation of doxorubicin and that resistance in these lines can be reversed by a calcium channel blocker has led to a clinical trial of verapamil plus doxorubicin in refractory ovarian cancer patients .
C0013089
doxorubicin
C0281009
verapamil